The robust IBD-SpA association underscores the need to optimize IBD therapy by targeting shared immune pathways (e.g., TNF-α [31], interleukin-23 (IL-23)/interleukin-17 (IL-17) [32]) to mitigate joint risks. This evidence concerns the gene IL17A and inflammatory bowel disease.